Review Article Contemplative understanding of Diabetes and diabetic Neuropathy

Authors

  • MD Ather Hussain Ansari  School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India
  • Atika Firdouse  School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India

Keywords:

Diabetes mellitus, type1DM, Type2DM, Pharmacotherapy, Diabetic Neuropathy.

Abstract

Diabetes mellitus has become a major public health concern around the world as a result of the rapid rise in prevalence that has occurred, affecting virtually all regions of the globe and within regions, affecting all age and demographic subgroups, and affecting people from all socioeconomic backgrounds. The global incidence is presently believed to be over 420 million, affecting 9% of males and 8% of women, with the lowest geographical frequency (6%) in Northeastern Europe and the highest prevalence (25%) in Polynesia and Macronesia. Both type 1 and type 2 diabetes have increased in prevalence, with type 2 accounting for 90 to 95 percent of occurrences and the majority of the increase in prevalence. . Diabetes consequences may be diversifying further due to long-term decreases in cardiovascular mortality in many countries, in addition to the effects of diabetes on classically characterized macrovascular and microvascular disorders. Neuropathy is the most common late complication of diabetes and can cause significant disability, including painful foot ulceration, Charcot joints, symptomatic autonomic dysfunction, and depression, anxiety, and sleep disorders. Neuropathy is a broad term that refers to nerve abnormalities. It is frequently and imprecisely used synonymously with polyneuropathy or peripheral neuropathy, the latter two being equivalent. Although substantial progress has been made in the last decade in terms of both customised diagnosis and therapy for T1D, significant challenges and research gaps still exist,between where we are today in terms of knowledge and where we want to go into a common clinical benefit. There is an urgent need for more well-conducted, big head-to-head comparative trials and combination trials of existing treatments. A variety of new therapeutic targets are currently being developed. Future clinical trials, on the other hand, should include procedures for detecting placebo effects to ensure that the genuine treatment benefit is recorded.

References

  1. Adebola Matthew Giwa, Rizwan Ahmed, Zahra Omidian, Neha Majety, Kagan Ege Karakus, Sarah M Omer,Thomas Donner, Abdel Rahim A Hamad; Current understandings of the pathogenesis of type 1 diabetes:Genetics to environment World J Diabetes, Volume 11.
  2. Anastasia Katsarou1, Soffia Gudbjörnsdottir2,3, Araz Rawshani2,3, Dana Dabelea4, Ezio Bonifacio5, Barbara J. Anderson6, Laura M. Jacobsen7, Desmond A. Schatz7 and Åke Lernmark; Type 1 diabetes mellitusNature reviews ;2017; VOLUME 3.
  3. Ammira AlShabeeb Akil, Esraa Yassin, Aljazi AlMaraghi, Elbay Aliyev, Khulod AlMalki and Khalid A. Fakhro; Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era.; Journal of Translational Medicine;2021; 19:137
  4. Bahendeka Silver . Kaushik Ramaiya . Swai Babu Andre .Otieno Fredrick . Sarita Bajaj . Sanjay Kalra . Bavuma M. Charlotte .Karigire Claudine . Anthony Makhoba ; EADSG Guidelines: Insulin Therapy in Diabetes; Diabetes Ther (2018) 9:449–492.
  5. Angela McGibbon, Cindy Richardson, Cheri Hernandez RN, John Dorna ; Pharmacotherapy in Type 1 Diabetes; Canadian Journal of Diabetes; 37 (2013) S56eS60.
  6. Sudesna Chatterjee, Kamlesh Khunti, Melanie J Davies; Type 2 diabetes; www.thelancet.com; 2017; http://dx.doi.org/10.1016/ S0140-6736(17)30058-2.
  7. Unai Galicia-Garcia, Asier Benito-Vicente, Shifa Jebari, Asier Larrea-Sebal,Haziq Siddiqi, Kepa B. Uribe, Helena Ostolaza, and César Martín; Pathophysiology of Type 2 Diabetes Mellitus;international journal of molecular sciences; 2020, 21, 6275.
  8. Ralph A. DeFronzo, Pathogenesis of type 2 diabetes mellitus;The Medical cinics of North America; 88 (2004) 787–835.
  9. Clifford J Bailey, Pablo Aschner, Stefano Del Prato, James LaSalle, Linong Ji and Stephan Matthaei; Individualized glycaemic targets and pharmacotherapy in type 2 diabetes; Diabetes & Vascular Disease Research; 2013; 10(5) 397–409.
  10. Rachel Agius; An update pharmacotherapy for type 2 diabetes; Malta Medical Journal;2014; 26,(04).
  11. John Wass, Katharine Owen, Helen Turner Oxford Handbook of Endocrinology and Diabetes; Third edition;2014;p-792.
  12. Joel Rodriguez-Saldana; The Diabetes Textbook Clinical Principles, Patient Management and Public Health Issues; Springer Nature Switzerland AG 2019.
  13. Brian C. Callaghan, Hsinlin Cheng, Catherine L. Stables, Andrea L. Smith, and Eva L. Feldman ;Diabetic neuropathy: Clinical manifestations and current treatments; Lancet Neurol. 2012 June ; 11(6): 521–534.
  14. Eva L. Feldman, Brian C. Callaghan, Rodica Pop-Busui, Douglas W. Zochodne, Douglas E. Wright, David L. Bennett, Vera Bril, James W. Russell, Vijay Viswanathan; Diabetic neuropathy;PMC; 2020; 5(1): 42.
  15. Ioannis N. Petropoulos, Georgios Ponirakis, Adnan Khan, Hamad Almuhannadi, Hoda Gad, Rayaz A. Malik; Diagnosing Diabetic Neuropathy: Something Old, Something New; Diabetes Metab J 2018;42:255-269.
  16. GE'RARD SAID; Diabetic neuropathy; Handbook of Clinical Neurology, Vol. 115 (3rd series); 2013 Elsevier.
  17. Daniela C. Rosenberger · Vivian Blechschmidt · Hans Timmerman · André Wolff · Rolf‑Detlef Treede; Challenges of neuropathic pain: focus on diabetic neuropathy; Journal of Neural Transmission; 2020.
  18. TRIANTAFYLLOS DIDANGELOS, JOHN DOUPIS, AND ARISTIDIS VEVES; Painful diabetic neuropathy: clinical aspects; Handbook of Clinical Neurology, Vol. 126 (3rd series); 2014 Elsevier.
  19. Prodromos Parasoglou,; SmitaRao; andJillM.Slade, Declining Skeletal Muscle Function in Diabetic Peripheral Neuropathy; Elsevier HS Journals; Clinical Therapeutics/Volume 2, 2017.
  20. Li Xu, Yuguan Zhang, and Yuguang Huang; Advances in the Treatment of Neuropathic Pain; Springer Science+Business Media Dordrecht 2016; DOI 10.1007/978-94-017-7537-3_9.
  21. Michael D. Staudt, Tarun Prabhala, Breanna L. Sheldon, Nicholas Quaranta, Michael Zakher, BA, Ravneet Bhullar, Julie G. Pilitsis, and Charles E. Argoff ; Current Strategies for the Management of Painful Diabetic Neuropathy; Journal of Diabetes Science and Technology; 2020; 1–12.
  22. Fahmy Amara, Sherif Hafez, Abbas Orabi, Adel El Etriby, Aly Ahmed Abdel Rahim, Ebtissam Zakaria, Farouk Koura, Farouk Mohamed Talaat, Hanan Gawish, Ihab Attia, Mohamed Fahmy Abdel Aziz, Mohamed Hesham Mohamed Fahmy El Hefnawy, Mohamed Kamar, Mohamed Reda Halawa, Mohamed Shawky El-Sayed, Nabil Abdelfatah El Kafrawy, Samir Helmy Assaad Khalil and Samir Naem Assaad; Review of Diabetic Polyneuropathy: Pathogenesis, Diagnosis and Management According to the Consensus of Egyptian Experts; Current Diabetes Reviews, 2019, 15, (4).

Downloads

Published

2021-08-30

Issue

Section

Research Articles

How to Cite

[1]
MD Ather Hussain Ansari, Atika Firdouse "Review Article Contemplative understanding of Diabetes and diabetic Neuropathy" International Journal of Scientific Research in Science and Technology(IJSRST), Online ISSN : 2395-602X, Print ISSN : 2395-6011,Volume 8, Issue 4, pp.402-425, July-August-2021.